Vaxart Dividends and Buybacks

Dividend criteria checks 0/6

Vaxart does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-41.0%

Buyback Yield

Total Shareholder Yield-41.0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if VXRT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VXRT's dividend payments have been increasing.


Dividend Yield vs Market

Vaxart Dividend Yield vs Market
How does VXRT dividend yield compare to the market?
SegmentDividend Yield
Company (VXRT)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Biotechs)2.4%
Analyst forecast (VXRT) (up to 3 years)n/a

Notable Dividend: Unable to evaluate VXRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VXRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate VXRT's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VXRT has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vaxart, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Charles DuncanCantor Fitzgerald & Co.
Vernon BernardinoH.C. Wainwright & Co.